Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualised relapse rate for up to 156 weeks compared to oral teriflunomide in both studies In two Phase III trials, evolutionRMS 1 and evolutionRMS 2, the compound known as evobrutinib failed to beat Sanofi’s established Aubagio in reducing MS relapse…
Category: Multiple Sclerosis
A prodrome for MS?
Study in Neurology evaluated the associations between diseases and symptoms diagnosed in primary care The researchers show that, on a population scale, the frequency of disorders such as depression, constipation, and urinary tract infections is associated with a diagnosis of multiple sclerosis five years later. These results outline a prodromal phase of the disease. Several studies have…
David Martin, CEO of the MS Trust to retire
David Martin has announced that following six years at the MS Trust, he plans to retire in early 2024. During his tenure at the MS Trust, David has overseen the establishment of both the Specialist Nurse and the Advanced MS Champion programmes. Working closely with the NHS, these schemes place Specialist MS Health Professionals in…
Switching to second line MS DMTs associated with decreased relapse rate
People with multiple sclerosis (MS) who switch between more than two disease-modifying therapies (DMTs) have a higher risk of relapses compared with those who never switch, regardless of how well these patients adhere to their prescribed medications, according to real-world study in Canada. According to the researchers, these findings are consistent with a greater number of treatment switches in…
Ketogenic diet in RRMS
Study suggests benefits may be long lasting Following a ketogenic diet for six months significantly reduced measures of body fat and fatigue, eased disease symptoms, and improved exercise capacity, cognition, and arm and hand dexterity in people with relapsing-remitting multiple sclerosis (RRMS), a study has shown. The research, Ketogenic diet in relapsing multiple sclerosis: Patient perceptions, post-trial…
Positive CHMP opinion for multiple sclerosis biosimilar natalizumab
July 24, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorisation for first-of-a-kind biosimilar natalizumab developed by Polpharma Biologics. The authorisation covers treatment as a single disease-modifying…
Subcutaneous Ocrevus injection – OCARINA II trial results
Phase III trial results could strengthen Ocrevus’s position in multiple sclerosis GlobalData, 19th July 2023: Genentech recently announced positive results from its phase III trial, OCARINA II (NCT05232825), investigating the efficacy of Ocrevus (ocrelizumab) as a subcutaneous injection, administered twice yearly for ten minutes, in patients diagnosed with relapsing multiple sclerosis (RMS) and primary progressive…
AI award for Queen Mary University of London and icometrix
Queen Mary and icometrix have together been awarded the prestigious AI Award in Health and Care by the National Institute for Health and Care Research (NIHR) 7th March 2023 The collaborative programme will investigate the impact of AI on the assessment of MRI and decision making for people with multiple sclerosis (MS). It is hoped…
Primary Progressive MS confirmed to be distinct from other MS subtypes
Long suspected by the research community, new study from Tisch MS Research Center of New York, published in Brain, finally establishes that PPMS is pathophysiologically separate from other forms of MS Findings have groundbreaking implications for targeted treatment of PPMS, a disease characterised by worsening neurological function and progressive disability in patients The Tisch MS…
